RIGL Q1 2022 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-79.3% YoY

Gross Profit

$17M99.3% margin

Operating Income

-$26M-156.9% margin

Net Income

-$27M-164.0% margin

EPS (Diluted)

$-1.60

QoQ Revenue Growth

-18.0%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$149M

Total Liabilities

$142M

Stockholders' Equity

$7M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$81M	-79.3%
Gross Profit	$17M	$81M	-79.4%
Operating Income	-$26M	$42M	-162.9%
Net Income	-$27M	$40M	-169.5%

Revenue Segments

Gross product sales

$23M68%

Product sales, net

$16M48%

Revenues from collaborations

$538,0002%

Research and development services and others

$330,0001%

License revenues

$208,0001%

Discounts and allowances

-$6M-19%